The multivalent toxoid vaccine made by LimmaTech Biologics, a Switzerland-based drug company, is designed to prevent skin and soft tissue infections caused by the bacterial pathogen. There are currently no FDA-approved vaccines for Staph aureus infections, according to a Dec. 19 news release.
By gaining the agency’s fast-track authorization, LimmaTech can discuss the clinical development plan for the vaccine, LBT-SA7, with the FDA more frequently than normal.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.